Thursday, 17 January 2019

Immunomedics' cancer treatment fails to win accelerated approval from the FDA

Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)